Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Galantamine Hydrobromide

FDA-approved product (tablet, oral), marketed as Galantamine Hydrobromide, Razadyne, Razadyne Er.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Galantamine Hydrobromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae89.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 1 of 1 lab record
Open Galantamine Hydrobromide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Galantamine Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

    NCT07625332 · start 2026-06-15

    Registered record
    Registry ID
    NCT07625332
    Conditions
    Spinal Cord Injury; Traumatic Spinal Cord Injury; Paraplegia and Tetraplegia; Metabolic Syndrome
    Interventions
    Galantamine Hydrobromide Extended Release
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-06-15
    Completion
    2027-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Traumatic Spinal Cord Injury; Paraplegia and Tetraplegia; Metabolic Syndrome
    InterventionGalantamine Hydrobromide Extended Release
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    NCT07633470 · start 2026-05-20

    Registered record
    Registry ID
    NCT07633470
    Conditions
    Alzheimer Disease
    Interventions
    Zunveyl®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-05-20
    Completion
    2027-04
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionZunveyl®
    PhasePhase 4
    Registry statusRecruiting

  • Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

    NCT07003386 · start 2025-09-15

    Registered record
    Registry ID
    NCT07003386
    Conditions
    Acute Ischemic Stroke AIS
    Interventions
    Galantamine; Standard treatment for acute ischemic stroke
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-09-15
    Completion
    2028-09-30
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke AIS
    InterventionGalantamine; Standard treatment for acute ischemic stroke
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease

    NCT07208344 · start 2025-07-31

    Registered record
    Registry ID
    NCT07208344
    Conditions
    Alzheimer Disease (AD)
    Interventions
    Intravenous infusion of mononuclear cells from umbilical cord blood; Conventional medical treatment：donepezil, rivastigmine or galantamine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2025-07-31
    Completion
    2026-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease (AD)
    InterventionIntravenous infusion of mononuclear cells from umbilical cord blood; Conventional medical treatment：donepezil, rivastigmine or galantamine
    PhaseEarly phase 1
    Registry statusRecruiting

  • Quality of the Management of Diabetes in Elderly People With Dementia in France

    NCT03565809 · start 2017-05-02

    Registered record
    Registry ID
    NCT03565809
    Conditions
    Alzheimer Disease
    Interventions
    Incidence analysis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-05-02
    Completion
    2018-12-31
    Enrolment
    87,816

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionIncidence analysis
    PhaseNot recorded
    Registry statusCompleted

  • Subarachnoid Hemorrhage Recovery And Galantamine

    NCT02872857 · start 2016-09

    Registered record
    Registry ID
    NCT02872857
    Conditions
    Subarachnoid Hemorrhage
    Interventions
    Placebo; 8mg galantamine twice daily; 12mg galantamine twice daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-09
    Completion
    2019-07-20
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage
    InterventionPlacebo; 8mg galantamine twice daily; 12mg galantamine twice daily
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • Galantamine Effects in Patients With Metabolic Syndrome

    NCT02283242 · start 2014-03

    Registered record
    Registry ID
    NCT02283242
    Conditions
    Abdominal Obesity Metabolic Syndrome
    Interventions
    Galantamine; Placebo (for galantamine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-03
    Completion
    2017-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbdominal Obesity Metabolic Syndrome
    InterventionGalantamine; Placebo (for galantamine)
    PhasePhase 4
    Registry statusCompleted

  • Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

    NCT01951118 · start 2013-10

    Registered record
    Registry ID
    NCT01951118
    Conditions
    Alzheimer Disease; Mild Cognitive Impairment; Delirium, Dementia, Amnestic, Cognitive Disorders
    Interventions
    Donepezil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2019-05
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Mild Cognitive Impairment; Delirium, Dementia, Amnestic, Cognitive Disorders
    InterventionDonepezil
    PhasePhase 4
    Registry statusCompleted

  • Effect of Galantamine on Short-term Abstinence

    NCT01669538 · start 2012-08

    Registered record
    Registry ID
    NCT01669538
    Conditions
    Tobacco Use Disorder
    Interventions
    Galantamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08
    Completion
    2017-11
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTobacco Use Disorder
    InterventionGalantamine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

    NCT01529619 · start 2012-03

    Registered record
    Registry ID
    NCT01529619
    Conditions
    Alzheimer's Disease
    Interventions
    Rivastigmine transdermal patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionRivastigmine transdermal patch
    PhasePhase 4
    Registry statusCompleted

  • Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

    NCT01531153 · start 2011-09

    Registered record
    Registry ID
    NCT01531153
    Conditions
    Addiction
    Interventions
    Galantamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-09
    Completion
    2016-06
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAddiction
    InterventionGalantamine; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

    NCT01416948 · start 2011-08

    Registered record
    Registry ID
    NCT01416948
    Conditions
    Posttraumatic Stress Disorder; Traumatic Brain Injury
    Interventions
    Methylphenidate Hydrochloride 20 mg; Placebo Capsule; Galantamine 12 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-08
    Completion
    2013-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder; Traumatic Brain Injury
    InterventionMethylphenidate Hydrochloride 20 mg; Placebo Capsule; Galantamine 12 mg
    PhasePhase 2
    Registry statusTerminated

  • The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

    NCT01181921 · start 2011-05

    Registered record
    Registry ID
    NCT01181921
    Conditions
    Alzheimer Disease
    Interventions
    Galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2011-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionGalantamine
    PhasePhase 4
    Registry statusTerminated

  • Effects of Galantamine on Cognition

    NCT01100775 · start 2010-05

    Registered record
    Registry ID
    NCT01100775
    Conditions
    Schizophrenia
    Interventions
    Galantamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2014-08-21
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionGalantamine; Placebo
    PhasePhase 2
    Registry statusCompleted